IL252192A0 - דיאנהידרוגאלאקטיטול יחד עם קרינה לטיפול בתאים לא קטנטנים של סרטן הריאה ו גליאובלסטומה רב-צורנית - Google Patents

דיאנהידרוגאלאקטיטול יחד עם קרינה לטיפול בתאים לא קטנטנים של סרטן הריאה ו גליאובלסטומה רב-צורנית

Info

Publication number
IL252192A0
IL252192A0 IL252192A IL25219217A IL252192A0 IL 252192 A0 IL252192 A0 IL 252192A0 IL 252192 A IL252192 A IL 252192A IL 25219217 A IL25219217 A IL 25219217A IL 252192 A0 IL252192 A0 IL 252192A0
Authority
IL
Israel
Prior art keywords
dianhydrogalactitol
lung
radiation
small
cell carcinoma
Prior art date
Application number
IL252192A
Other languages
English (en)
Other versions
IL252192B2 (he
IL252192B1 (he
Original Assignee
Del Mar Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Del Mar Pharmaceuticals filed Critical Del Mar Pharmaceuticals
Publication of IL252192A0 publication Critical patent/IL252192A0/he
Publication of IL252192B1 publication Critical patent/IL252192B1/he
Publication of IL252192B2 publication Critical patent/IL252192B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL252192A 2014-11-10 2015-11-10 דיאנהידרוגאלאקטיטול יחד עם קרינה לטיפול בתאים לא קטנטנים של סרטן הריאה ו גליאובלסטומה רב–צורנית IL252192B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077712P 2014-11-10 2014-11-10
PCT/US2015/059814 WO2016077264A1 (en) 2014-11-10 2015-11-10 Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme

Publications (3)

Publication Number Publication Date
IL252192A0 true IL252192A0 (he) 2017-07-31
IL252192B1 IL252192B1 (he) 2023-11-01
IL252192B2 IL252192B2 (he) 2024-03-01

Family

ID=55954912

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252192A IL252192B2 (he) 2014-11-10 2015-11-10 דיאנהידרוגאלאקטיטול יחד עם קרינה לטיפול בתאים לא קטנטנים של סרטן הריאה ו גליאובלסטומה רב–צורנית

Country Status (14)

Country Link
US (1) US20190015379A1 (he)
EP (1) EP3217970A4 (he)
JP (3) JP2017536356A (he)
KR (2) KR20170081261A (he)
CN (2) CN107231794A (he)
AU (1) AU2015346598B2 (he)
BR (1) BR112017009845A2 (he)
CA (1) CA2967322A1 (he)
CL (1) CL2017001180A1 (he)
IL (1) IL252192B2 (he)
MX (1) MX2017006076A (he)
SG (1) SG11201703810QA (he)
TW (1) TW201632181A (he)
WO (1) WO2016077264A1 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015379A1 (en) * 2014-11-10 2019-01-17 Delmar Pharmaceuticals, Inc. Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells
US11715549B2 (en) * 2017-05-01 2023-08-01 Thomas Jefferson University Systems-level analysis of 32 TCGA cancers reveals disease-dependent tRNA fragmentation patterns and very selective associations with messenger RNAs and repeat elements
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
CN109512833B (zh) * 2018-12-04 2020-10-30 天津医科大学总医院 E2f6抑制剂的功能与用途
US20230210803A1 (en) * 2020-04-09 2023-07-06 L.E.A.F. Holdings Group Llc Trans-crocetin compositions and treatment regimens
KR102560912B1 (ko) * 2020-08-26 2023-07-28 한양대학교 에리카산학협력단 엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
CN113599524B (zh) * 2021-09-02 2023-05-02 中国医学科学院肿瘤医院 Hnrnpc和rbmx作为靶点在制备治疗小细胞肺癌的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
PL2310011T3 (pl) * 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
KR20140022750A (ko) * 2010-08-18 2014-02-25 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨 및 디아세틸디안하이드로갈락티톨과 같은 치환된 헥시톨을 포함하는 준최적하게 투여되는 화학적 화합물의 치료상 이점을 향상시키기 위한 조성물 및 방법
BR112014017833A2 (pt) * 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
CN106659765B (zh) * 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
US20190015379A1 (en) * 2014-11-10 2019-01-17 Delmar Pharmaceuticals, Inc. Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells

Also Published As

Publication number Publication date
KR20170081261A (ko) 2017-07-11
CA2967322A1 (en) 2016-05-19
EP3217970A1 (en) 2017-09-20
KR20230008252A (ko) 2023-01-13
TW201632181A (zh) 2016-09-16
CN115414480A (zh) 2022-12-02
SG11201703810QA (en) 2017-06-29
JP2020183445A (ja) 2020-11-12
AU2015346598A1 (en) 2017-06-08
EP3217970A4 (en) 2018-07-18
IL252192B2 (he) 2024-03-01
MX2017006076A (es) 2017-12-11
US20190015379A1 (en) 2019-01-17
IL252192B1 (he) 2023-11-01
WO2016077264A1 (en) 2016-05-19
BR112017009845A2 (pt) 2018-01-16
CL2017001180A1 (es) 2017-12-29
JP2022174200A (ja) 2022-11-22
JP2017536356A (ja) 2017-12-07
CN107231794A (zh) 2017-10-03
AU2015346598B2 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
IL272820B (he) תולדות סולפאמוילפירולאמיד והשימוש בהן כתרופות לטיפול בצהבת b
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL248189B (he) שימוש בחומרים מסוג דיאנהידרוגלאקטיקול לטיפול בסרטן ריאות וסרטן שחלות
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
ZA201602380B (en) Cancer treatment with combination of plinabulin and taxane
IL252192A0 (he) דיאנהידרוגאלאקטיטול יחד עם קרינה לטיפול בתאים לא קטנטנים של סרטן הריאה ו גליאובלסטומה רב-צורנית
IL276733A (he) שימוש באריבולין בטיפול בסרטן
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
GB2516335B (en) The use of phytocannabinoids in the treatment of ovarian carcinoma
IL248767B (he) תרכובות טרימתוקסיפניל–בנזאימידאזול לטיפול בסרטן
IL251903B (he) אפילימוד לשימוש בטיפול של סרטן המעי הגס
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer
GB201403086D0 (en) Selection of virus and agent useful in the treatment of cancer
SG10201802995SA (en) Cancer treatment with combination of plinabulin and taxane